Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT ID: NCT00628095
Last Updated: 2022-04-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2008-04-07
2009-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
NCT00446784
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
NCT00424294
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
NCT00413660
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
NCT00960440
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
NCT00847613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
CE-224,535
500 mg po BID
Placebo
Placebo
no active ingredient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CE-224,535
500 mg po BID
Placebo
no active ingredient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Incomplete response to methotrexate
Exclusion Criteria
* No recent infections
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Arthritis & Rheumatology Associates, P.C.
Mesa, Arizona, United States
Omega Research Consultants LLC
DeBary, Florida, United States
Florida Arthritis Center
Lake Mary, Florida, United States
Tampa Medical Group, PA
Tampa, Florida, United States
American Health Network
Avon, Indiana, United States
Best Clinical Trials, LLC (Administrative Only)
New Orleans, Louisiana, United States
George Stanley Walker, MD
New Orleans, Louisiana, United States
Majid Abdul Jawad, MD
New Orleans, Louisiana, United States
The Arthritis and Osteoporosis Center of Maryland
Frederick, Maryland, United States
University Physicians
Columbia, Missouri, United States
University of Missouri-Columbia
Columbia, Missouri, United States
Arthritis Center of Reno
Reno, Nevada, United States
New Horizons Clinical Research
Cincinnati, Ohio, United States
Arthritis Northwest
Spokane, Washington, United States
Clínica Santa María, Sección Reumatología
Providencia, Santiago, RM, Chile
Revmatologicka ambulance
Česká Lípa, , Czechia
Revmatologicky ustav
Prague, , Czechia
Revmatologicka ambulance
Prague, , Czechia
Investigadores Clinicos Asociados
México, D.F., Mexico
Krakowskie Centrum Medyczne NZOZ
Krakow, , Poland
Zaklad Reumatologii i Immunologii Klinicznej
Poznan, , Poland
Oddzial Reumatologiczno-Rehabilitacyjny IIR Ortopedyczno-Rehabilitacyjny
Poznan, , Poland
Inha University Hospital, Medicine/Rheumatology
Incheon, , South Korea
Pusan National University Hospital, Rheumatology, Internal Medicine
Pusan, , South Korea
Hospital Nuestra Señora de La Esperanza
Santiago de Compostela, A Coruña, Spain
Complexo Hospitalario Universitario A Coruña
A Coruña, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, Mebus CA. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7. doi: 10.3899/jrheum.110874. Epub 2012 Mar 1.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-000327-25
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A6341009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.